0001209191-20-051037.txt : 20200917 0001209191-20-051037.hdr.sgml : 20200917 20200917191330 ACCESSION NUMBER: 0001209191-20-051037 CONFORMED SUBMISSION TYPE: 4 PUBLIC DOCUMENT COUNT: 1 CONFORMED PERIOD OF REPORT: 20200915 FILED AS OF DATE: 20200917 DATE AS OF CHANGE: 20200917 REPORTING-OWNER: OWNER DATA: COMPANY CONFORMED NAME: Williams Kristen Marie CENTRAL INDEX KEY: 0001296965 FILING VALUES: FORM TYPE: 4 SEC ACT: 1934 Act SEC FILE NUMBER: 001-35060 FILM NUMBER: 201182326 MAIL ADDRESS: STREET 1: C/O PACIRA PHARMACEUTICALS, INC. STREET 2: 5 SYLVAN WAY, SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER NAME: FORMER CONFORMED NAME: Dunker Kristen Marie DATE OF NAME CHANGE: 20040712 ISSUER: COMPANY DATA: COMPANY CONFORMED NAME: Pacira BioSciences, Inc. CENTRAL INDEX KEY: 0001396814 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 510619477 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 BUSINESS ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 BUSINESS PHONE: 973-254-3560 MAIL ADDRESS: STREET 1: 5 SYLVAN WAY STREET 2: SUITE 300 CITY: PARSIPPANY STATE: NJ ZIP: 07054 FORMER COMPANY: FORMER CONFORMED NAME: Pacira Pharmaceuticals, Inc. DATE OF NAME CHANGE: 20101029 FORMER COMPANY: FORMER CONFORMED NAME: PACIRA INC DATE OF NAME CHANGE: 20080318 FORMER COMPANY: FORMER CONFORMED NAME: Blue Acquisition Corp DATE OF NAME CHANGE: 20070418 4 1 doc4.xml FORM 4 SUBMISSION X0306 4 2020-09-15 0 0001396814 Pacira BioSciences, Inc. PCRX 0001296965 Williams Kristen Marie C/O PACIRA BIOSCIENCES, INC. 5 SYLVAN WAY, SUITE 300 PARSIPPANY NJ 07054 0 1 0 0 Chief Administrative Officer Common Stock 2020-09-15 4 M 0 5832 40.34 A 30719 D Common Stock 2020-09-15 4 M 0 5832 32.35 A 36551 D Common Stock 2020-09-15 4 M 0 5499 44.20 A 42050 D Common Stock 2020-09-15 4 M 0 7874 38.35 A 49924 D Common Stock 2020-09-15 4 M 0 2816 43.54 A 52740 D Common Stock 2020-09-15 4 S 0 14622 59.01 D 38118 D Common Stock 2020-09-15 4 S 0 13231 59.80 D 24887 D Common Stock 2020-09-16 4 M 0 5832 40.34 A 30719 D Common Stock 2020-09-16 4 M 0 5832 32.35 A 36551 D Common Stock 2020-09-16 4 M 0 5499 44.20 A 42050 D Common Stock 2020-09-16 4 M 0 7874 38.35 A 49924 D Common Stock 2020-09-16 4 M 0 2816 43.54 A 52740 D Common Stock 2020-09-16 4 S 0 6609 59.54 D 46131 D Common Stock 2020-09-16 4 S 0 21244 60.33 D 24887 D Common Stock 2020-09-17 4 M 0 5836 40.34 A 30723 D Common Stock 2020-09-17 4 M 0 5836 32.35 A 36559 D Common Stock 2020-09-17 4 M 0 5502 44.20 A 42061 D Common Stock 2020-09-17 4 M 0 7878 38.35 A 49939 D Common Stock 2020-09-17 4 M 0 2819 43.54 A 52758 D Common Stock 2020-09-17 4 S 0 24671 59.77 D 28087 D Common Stock 2020-09-17 4 S 0 3200 60.22 D 24887 D Stock Option (Right to Buy) 40.34 2020-09-15 4 M 0 5832 0.00 D 2026-06-15 Common Stock 5832 11668 D Stock Option (Right to Buy) 32.35 2020-09-15 4 M 0 5832 0.00 D 2026-12-07 Common Stock 5832 14168 D Stock Option (Right to Buy) 44.20 2020-09-15 4 M 0 5499 0.00 D 2027-06-14 Common Stock 5499 16501 D Stock Option (Right to Buy) 38.35 2020-09-15 4 M 0 7874 0.00 D 2028-06-13 Common Stock 7874 39376 D Stock Option (Right to Buy) 43.54 2020-09-15 4 M 0 2816 0.00 D 2029-06-05 Common Stock 2816 30984 D Stock Option (Right to Buy) 40.34 2020-09-16 4 M 0 5832 0.00 D 2026-06-15 Common Stock 5832 5836 D Stock Option (Right to Buy) 32.35 2020-09-16 4 M 0 5832 0.00 D 2026-12-07 Common Stock 5832 8336 D Stock Option (Right to Buy) 44.20 2020-09-16 4 M 0 5499 0.00 D 2027-06-14 Common Stock 5499 11002 D Stock Option (Right to Buy) 38.35 2020-09-16 4 M 0 7874 0.00 D 2028-06-13 Common Stock 7874 31502 D Stock Option (Right to Buy) 43.54 2020-09-16 4 M 0 2816 0.00 D 2029-06-05 Common Stock 2816 28168 D Stock Option (Right to Buy) 40.34 2020-09-17 4 M 0 5836 0.00 D 2026-06-15 Common Stock 5836 0 D Stock Option (Right to Buy) 32.35 2020-09-17 4 M 0 5836 0.00 D 2026-12-07 Common Stock 5836 2500 D Stock Option (Right to Buy) 44.20 2020-09-17 4 M 0 5502 0.00 D 2027-06-14 Common Stock 5502 5500 D Stock Option (Right to Buy) 38.35 2020-09-17 4 M 0 7878 0.00 D 2028-06-13 Common Stock 7878 23624 D Stock Option (Right to Buy) 43.54 2020-09-17 4 M 0 2819 0.00 D 2029-06-05 Common Stock 2819 25349 D The option exercises and sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan previously adopted by the reporting person in accordance with Rule 10b5-1 of the Securities Exchange Act of 1934. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.455 to $59.445, inclusive. The reporting person undertakes to provide to the issuer, any shareholder of the issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes 2 through 7. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.455 to $60.100, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $58.990 to $59.980, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.005 to $60.915, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $59.130 to $60.120, inclusive. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $60.130 to $60.370, inclusive. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vested as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remained in continuous service with the issuer as of each vesting date. The stock option vested and became exercisable as to 25% of the option shares on the first anniversary of the grant date, and vests as to the remaining shares in successive equal quarterly installments over the subsequent three years, provided that the reporting person remains in continuous service with the issuer as of each vesting date. /s/ Kristen Williams 2020-09-17